|
Selected publication
|
- Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators (Chen Y-H). 2017. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 376(4): 305-17. (SCI) (IF=96.2,2023)
- Wang CY, Wong WW, Tsai HC, Chen Y-H, Kuo BS, Lynn S, Blazkov J, Clarri DK, Su HW, Lin CY, Tseng FC, Annie L, Lin CH, Tseng W, Lin HY, Connie F, Wong-Staal F, Chun TW, Liao MJ. 2019. Impact of anti-CD4 antibody UB-421 on HIV rebound after treatment interruption. N Engl J Med. 380:1535-45.(SCI) (IF=96.2,2023)
- Hsieh SM, Liu MC, Chen Y-H, Lee WS, Hwang SJ, Cheng SH, Ko WC, Hwang KP, Wang NC, Lee YL, Lin YL, Shih SR, Huang CG, Liao CC, Liang JJ, Chang CS, Chen C, Lien CE, Tai IC, Lin TY. 2021. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Lancet Respir Med. 9(12):1396-406. (SCI) (IF=38.7,2023)
- Thompson 3rd GR, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG, ReSTORE trial investigators (Chen Y-H). 2023. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 401(10370):49-59. (IF=98.4,2023)
|
